Prognostic Significance of LncRNA PVT1 and Its Potential Target Gene Network in Human Cancers: a Comprehensive Inquiry Based Upon 21 Cancer Types and 9972 Cases

Abstract

Background/Aims: Whether the level of long noncoding RNA plasmacytoma variant translocation 1 gene (lncRNA PVT1) expression influences the clinical development and outcome of human cancers has not been thoroughly elucidated to date. Inconsistencies still exist regarding the associations between PVT1 and the clinicopathological features, including patient survival data. Additionally, the regulatory mechanism of PVT1 among human cancers remains unclear. Methods: we conducted a comprehensive inquiry to verify the implication of PVT1 expression in cancer patients by conducting a meta-analysis of 19 selected studies and The Cancer Genome Atlas (TCGA) database to examine the relationship between PVT1 expression and both the prognosis and clinicopathological features of cancer patients using STATA 12.0. In addition, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of the potential mRNA target genes of PVT1 gathered from TANRIC and Multi Experiment Matrix (MEM) were performed. Results: The level of PVT1 expression in tumor tissues was higher than in paired non-cancer tissues and was significantly associated with a poorer prognosis in cancer patients. Additionally, overexpression of PVT1 was significantly correlated with histological differentiation, tumor (T) classification, lymph node (N) classification and TNM stages. Furthermore, a total of 462 validated target genes were identified, and the GO and KEGG analyses demonstrated that the validated targets of PVT1 were significantly enriched in several pathways, including the GnRH signaling pathway, the Cytokine-cytokine receptor interaction pathway, the Inflammatory mediator regulation of TRP channels pathway, and the Neuroactive ligand-receptor interaction pathway. Conclusion: PVT1 may serve as a potential biomarker associated with the progression and prognosis of human cancers.

Silencing of LncRNA PVT1 inhibits the proliferation, migration and fibrosis of high glucose-induced mouse mesangial cells via targeting microRNA-93-5p

“…LncRNAs can modulate the translation and degradation of mR-NAs through interacting with microRNAs (miRs) [17]. The biological function of PTV1 during the disease process is realized by targeting specific miRs [18]. Six locations on PVT1 are revealed on miR-1204, -1205, -1206, 1207-3p, -1207-5p, and -1208 [19].…”

A Comprehensive Exploration of the lncRNA CCAT2: A Pan-Cancer Analysis Based on 33 Cancer Types and 13285 Cases

“…The following relevant information from all eligible studies was extracted: first author name, publication year, country, cancer type, sample size, assay method, the criterion for dividing CCAT2 into high and low groups, follow-up time, prognostic data, age classification, gender ratio, tumor size, clinical stage, TNM classification, and histological differentiation. If the paper does not provide complete survival data, we follow the methods of He et al [ 7 ]. The HR and 95% CI were extracted indirectly from the Kaplan-Meier survival curve using Engauge Digitizer version 11.2 ( https://github.com/markummitchell/engauge-digitizer/releases ).…”

“…Therefore, lncRNA is used as a biomarker to monitor tumor prognosis. For example, He et al explored the association between lncRNA PVT1 and patient prognosis in the TCGA database and sought after some possible pathways of PVT1 [7].…”

Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin

“…Conversely, in the general AML population, controversial results have been reported regarding PVT1 expression levels in bone marrow (BM) blasts compared with healthy donors [43,45,73]. However, different groups agreed on the increased PVT1 level in acute promyelocytic leukemia (APL), compared with mononuclear cells [45] or granulocytes [46] from healthy donors.…”